International Journal of Cancer Management

Published by: Kowsar

Cancer Antigen 125 (CA125), Human Epididymis Protein 4 (HE4), Risk of Malignancy Index (RMI), and Risk of Ovarian Malignancy Algorithm (ROMA) as Diagnostic Tests in Ovarian Cancer

Zinatossadat Bouzari 1 , Hadiseh Rahimi 2 , Hemmat Gholinia 3 , Shahla Yazdani 4 , * , Karimollah Hajian-Tilaki 5 and Mohammad Jafar Soleimani 6
Authors Information
1 Infertility and Reproductive Health Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
2 Babol University of Medical Sciences, Babol, Iran
3 The Clinical Research Development Unit of Rouhani Hospital, Health Research Center, Babol University of Medical Sciences, Babol, Iran
4 Cancer Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
5 Department of Biostatistics and Epidemiology, Babol University of Medical Sciences, Babol, Iran
6 Infectious Diseases Research Center, Babol University of Medical Sciences, Babol, Iran
Article information
  • International Journal of Cancer Management: January 31, 2019, 12 (1); e59395
  • Published Online: January 6, 2019
  • Article Type: Research Article
  • Received: August 3, 2017
  • Revised: December 13, 2018
  • Accepted: December 16, 2018
  • DOI: 10.5812/ijcm.59395

To Cite: Bouzari Z, Rahimi H , Gholinia H, Yazdani S, Hajian-Tilaki K , et al. Cancer Antigen 125 (CA125), Human Epididymis Protein 4 (HE4), Risk of Malignancy Index (RMI), and Risk of Ovarian Malignancy Algorithm (ROMA) as Diagnostic Tests in Ovarian Cancer, Int J Cancer Manag. 2019 ; 12(1):e59395. doi: 10.5812/ijcm.59395.

Abstract
Copyright © 2019, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86. doi: 10.1002/ijc.29210. [PubMed: 25220842].
  • 2. Sharifian A, Pourhoseingholi MA, Norouzinia M, Vahedi M. Ovarian cancer in Iranian women, a trend analysis of mortality and incidence. Asian Pac J Cancer Prev. 2014;15(24):10787-90. doi: 10.7314/APJCP.2014.15.24.10787. [PubMed: 25605177].
  • 3. Evans J, Ziebland S, McPherson A. Minimizing delays in ovarian cancer diagnosis: An expansion of Andersen's model of 'total patient delay'. Fam Pract. 2007;24(1):48-55. doi: 10.1093/fampra/cml063. [PubMed: 17158183].
  • 4. Fujiwara H, Suzuki M, Takeshima N, Takizawa K, Kimura E, Nakanishi T, et al. Evaluation of human epididymis protein 4 (HE4) and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women. Tumour Biol. 2015;36(2):1045-53. doi: 10.1007/s13277-014-2738-7. [PubMed: 25326813]. [PubMed Central: PMC4342513].
  • 5. Paulsen T, Kjaerheim K, Kaern J, Tretli S, Trope C. Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals. Int J Gynecol Cancer. 2006;16 Suppl 1:11-7. doi: 10.1111/j.1525-1438.2006.00319.x. [PubMed: 16515561].
  • 6. Valentin L. Use of morphology to characterize and manage common adnexal masses. Best Pract Res Clin Obstet Gynaecol. 2004;18(1):71-89. doi: 10.1016/j.bpobgyn.2003.10.002. [PubMed: 15123059].
  • 7. Karlan BY. The status of ultrasound and color Doppler imaging for the early detection of ovarian carcinoma. Cancer Invest. 1997;15(3):265-9. doi: 10.3109/07357909709039725. [PubMed: 9171861].
  • 8. Anton C, Carvalho FM, Oliveira EI, Maciel GA, Baracat EC, Carvalho JP. A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses. Clinics (Sao Paulo). 2012;67(5):437-41. [PubMed: 22666786]. [PubMed Central: PMC3351260].
  • 9. Zurawski VR Jr, Knapp RC, Einhorn N, Kenemans P, Mortel R, Ohmi K, et al. An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma. Gynecol Oncol. 1988;30(1):7-14. doi: 10.1016/0090-8258(88)90039-X. [PubMed: 2452773].
  • 10. Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol. 2005;99(2):267-77. doi: 10.1016/j.ygyno.2005.06.040. [PubMed: 16061277].
  • 11. Jacobs I, Bast RC Jr. The CA 125 tumour-associated antigen: A review of the literature. Hum Reprod. 1989;4(1):1-12. doi: 10.1093/oxfordjournals.humrep.a136832. [PubMed: 2651469].
  • 12. Buamah P. Benign conditions associated with raised serum CA-125 concentration. J Surg Oncol. 2000;75(4):264-5. doi: 10.1002/1096-9098(200012)75:4<264::AID-JSO7>3.0.CO;2-Q. [PubMed: 11135268].
  • 13. Yazdani S, Alijanpoor A, Sharbatdaran M, Bouzari Z, Abedisamakoosh M, Lakaieandi F, et al. Meigs' syndrome with elevated serum CA125 in a case of ovarian fibroma /thecoma. Caspian J Intern Med. 2014;5(1):43-5. [PubMed: 24490014]. [PubMed Central: PMC3894471].
  • 14. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol. 1990;97(10):922-9. doi: 10.1111/j.1471-0528.1990.tb02448.x. [PubMed: 2223684].
  • 15. Bailey J, Tailor A, Naik R, Lopes A, Godfrey K, Hatem HM, et al. Risk of malignancy index for referral of ovarian cancer cases to a tertiary center: does it identify the correct cases? Int J Gynecol Cancer. 2006;16 Suppl 1:30-4. doi: 10.1111/j.1525-1438.2006.00468.x. [PubMed: 16515564].
  • 16. Bouzari Z, Yazdani S, Shirkhani Kelagar Z, Abbaszadeh N. Risk of malignancy index as an evaluation of preoperative pelvic mass. Caspian J Intern Med. 2011;2(4):331-5. [PubMed: 24551441]. [PubMed Central: PMC3895832].
  • 17. Moore RG, Jabre-Raughley M, Brown AK, Robison KM, Miller MC, Allard WJ, et al. Comparison of a novel multiple marker assay vs the risk of malignancy index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol. 2010;203(3):228 e1-6. doi: 10.1016/j.ajog.2010.03.043. [PubMed: 20471625]. [PubMed Central: PMC3594101].
  • 18. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008;108(2):402-8. doi: 10.1016/j.ygyno.2007.10.017. [PubMed: 18061248].
  • 19. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009;112(1):40-6. doi: 10.1016/j.ygyno.2008.08.031. [PubMed: 18851871]. [PubMed Central: PMC3594094].
  • 20. Sandri MT, Bottari F, Franchi D, Boveri S, Candiani M, Ronzoni S, et al. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: Correlation with pathological outcome. Gynecol Oncol. 2013;128(2):233-8. doi: 10.1016/j.ygyno.2012.11.026. [PubMed: 23200911].
  • 21. Bouzari Z, Yazdani S, Ahmadi MH, Barat S, Kelagar ZS, Kutenaie MJ, et al. Comparison of three malignancy risk indices and CA-125 in the preoperative evaluation of patients with pelvic masses. BMC Res Notes. 2011;4:206. doi: 10.1186/1756-0500-4-206. [PubMed: 21689405]. [PubMed Central: PMC3224480].
  • 22. Giede KC, Kieser K, Dodge J, Rosen B. Who should operate on patients with ovarian cancer? An evidence-based review. Gynecol Oncol. 2005;99(2):447-61. doi: 10.1016/j.ygyno.2005.07.008. [PubMed: 16126262].
  • 23. Earle CC, Schrag D, Neville BA, Yabroff KR, Topor M, Fahey A, et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst. 2006;98(3):172-80. doi: 10.1093/jnci/djj019. [PubMed: 16449677].
  • 24. Kumpulainen S, Kuoppala T, Leminen A, Penttinen J, Puistola U, Pukkala E, et al. Surgical treatment of ovarian cancer in different hospital categories--a prospective nation-wide study in Finland. Eur J Cancer. 2006;42(3):388-95. doi: 10.1016/j.ejca.2005.09.029. [PubMed: 16414260].
  • 25. Ulusoy S, Akbayir O, Numanoglu C, Ulusoy N, Odabas E, Gulkilik A. The risk of malignancy index in discrimination of adnexal masses. Int J Gynaecol Obstet. 2007;96(3):186-91. doi: 10.1016/j.ijgo.2006.10.006. [PubMed: 17280665].
  • 26. Van Gorp T, Cadron I, Despierre E, Daemen A, Leunen K, Amant F, et al. HE4 and CA125 as a diagnostic test in ovarian cancer: Prospective validation of the risk of ovarian malignancy algorithm. Br J Cancer. 2011;104(5):863-70. doi: 10.1038/sj.bjc.6606092. [PubMed: 21304524]. [PubMed Central: PMC3048204].
  • 27. Karlsen MA, Sandhu N, Hogdall C, Christensen IJ, Nedergaard L, Lundvall L, et al. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2012;127(2):379-83. doi: 10.1016/j.ygyno.2012.07.106. [PubMed: 22835718].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments